Prolia (Denosumab) Cost in Colorado 2026: Pricing, Insurance, and Savings Options

What Does Prolia (Denosumab) Cost in Colorado in 2026?

The manufacturer list price for a single 60 mg prefilled syringe of Prolia is approximately $1,500. Colorado retail pharmacies mirror this national average almost exactly, with cash-pay quotes ranging from $1,450 to $1,580 across Denver, Colorado Springs, and Fort Collins locations as of early 2026.

Because Prolia is dosed every six months, the annual cash-pay cost runs roughly $3,000 per year before any insurance or discount. That figure places it well above oral bisphosphonates like alendronate, which cost $10 to $30 per month at most Colorado pharmacies. The price gap explains why most insurers and Medicaid programs restrict denosumab to second-line or third-line use.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo [1]. That efficacy profile supports its placement as a preferred agent for patients who cannot tolerate or have failed bisphosphonate therapy, per the Endocrine Society's 2019 clinical practice guideline [2].

For commercially insured patients in Colorado, out-of-pocket costs vary dramatically. Some plans classify Prolia under medical benefit (covered at the physician's office during administration), while others place it under pharmacy benefit with specialty tier copays ranging from $50 to $500 per dose [3].

Colorado Medicaid Coverage for Prolia

Colorado Medicaid does not cover Prolia for osteoporosis. Coverage is restricted to type 2 diabetes indications only, which makes Colorado an outlier among western states.

This restriction means that the roughly 800,000 Coloradans enrolled in Health First Colorado who have osteoporosis cannot access denosumab through their Medicaid benefit, regardless of fracture history or bisphosphonate intolerance. The American Association of Clinical Endocrinologists (AACE) 2020 guideline recommends denosumab as a first-line option for patients at very high fracture risk, defined as those with a recent fracture, T-score of <-3.0, or high FRAX probability [4]. Colorado Medicaid's formulary does not align with this recommendation for its osteoporosis population.

Patients on Medicaid who need denosumab for osteoporosis have a few alternatives. They can apply for Amgen's patient assistance program (Amgen Safety Net Foundation), which provides Prolia at no cost to patients with household incomes at or below 300% of the federal poverty level. The program requires documentation of insurance denial [5]. They can also explore 503A compounded denosumab, discussed below.

A prior authorization request for off-formulary coverage is possible but rarely approved. The Colorado Department of Health Care Policy & Financing publishes its preferred drug list quarterly, and denosumab has remained off the osteoporosis formulary since 2023 [6].

Commercial Insurance and Step Therapy Requirements

Most commercial insurers in Colorado cover Prolia after the patient has tried and failed at least one oral bisphosphonate. Step therapy typically requires 90 days on alendronate or risedronate with documented intolerance or inadequate response.

Anthem Blue Cross Blue Shield of Colorado, Kaiser Permanente Colorado, and Cigna all follow this pattern. United Healthcare plans in the state often require both a bisphosphonate trial and a documented T-score of <-2.5 or a prior fragility fracture before approving denosumab [7]. The prior authorization process generally takes 5 to 14 business days.

For patients covered under medical benefit (administered in a physician's office), the coinsurance rate is typically 10% to 20% after deductible. On a $1,500 injection, that translates to $150 to $300 per dose before the Amgen savings card is applied.

The FDA-approved prescribing information for Prolia specifies its indication for postmenopausal women with osteoporosis at high risk for fracture, men with osteoporosis at high risk for fracture, and patients receiving glucocorticoid therapy at high risk for fracture [8]. Insurers who restrict coverage to postmenopausal women may deny claims for male patients or glucocorticoid-induced osteoporosis, requiring an appeal with clinical documentation.

Dr. Michael McClung, director of the Oregon Osteoporosis Center, has noted: "Denosumab offers a unique mechanism of action as a RANKL inhibitor that provides consistent bone density gains year over year, but access barriers remain the biggest obstacle for many patients" [9]. That observation holds especially true in Colorado, where Medicaid exclusions and step therapy create a two-tier access system.

How the Amgen Savings Card Works in Colorado

The Amgen FIRST STEP program reduces copays for commercially insured patients to as low as $0 per injection, with a maximum annual benefit of $1,500 per calendar year.

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, or any government-funded program). They must be prescribed Prolia for an FDA-approved indication. Colorado residents can enroll at the point of prescribing, either through their physician's office or by calling the Amgen support line. The card covers both the drug cost and, in some cases, a portion of the administration fee.

One critical limitation: the savings card benefit resets each calendar year, and it does not count toward the patient's insurance deductible or out-of-pocket maximum. Patients who rely on the card early in the year may face full-price exposure on other medications later. The annual cap of $1,500 exactly matches one Prolia injection, so patients receiving two doses per year may see partial coverage on the second dose depending on their plan's copay structure.

For patients whose commercial copay exceeds $1,500 per dose (rare, but possible on high-deductible health plans), the savings card covers up to its maximum, and the remaining balance applies to the patient's deductible.

Compounded Denosumab in Colorado: 503A Pharmacy Access

Compounded denosumab is legally available in Colorado through licensed 503A pharmacies. These pharmacies compound the drug based on a valid patient-specific prescription and operate under state board of pharmacy oversight.

Colorado follows the federal framework established by the Drug Quality and Security Act of 2013, which distinguishes between 503A (patient-specific compounding) and 503B (outsourcing facilities). A 503A pharmacy in Colorado can compound denosumab if it holds a valid state license, compounds based on an individual prescription, and does not produce the drug in bulk without patient-specific orders [10].

The cost advantage is significant. While brand-name Prolia runs $1,500 per injection, compounded denosumab from a 503A pharmacy can be substantially less, though pricing varies by pharmacy and is not standardized across the state. Patients considering this route should confirm that their prescriber is willing to write for compounded denosumab and that the compounding pharmacy sources pharmaceutical-grade ingredients with certificates of analysis.

The FDA's guidance on compounding emphasizes that compounded drugs are not FDA-approved and have not undergone the same premarket review for safety, efficacy, or manufacturing quality as approved products [11]. Patients and prescribers should weigh cost savings against this regulatory distinction.

Biologic compounding raises unique considerations. Denosumab is a monoclonal antibody, and reproducing its structure requires precision that differs from small-molecule compounding. The U.S. Pharmacopeia (USP) Chapter 797 governs sterile compounding standards, and any 503A pharmacy producing injectable denosumab must comply with these requirements.

Telehealth Prescribing of Prolia in Colorado

Colorado permits telehealth prescribing of Prolia, meaning the initial consultation, prior authorization support, and prescription can all happen remotely. The actual injection still requires an in-person visit.

Colorado's telehealth parity law (SB 20-212) requires insurers to cover telehealth services at the same rate as in-person visits, which means the consultation portion of a denosumab prescription should not cost the patient more via telehealth [12]. This is particularly relevant for patients in rural Colorado. Residents of the Western Slope, San Luis Valley, or Eastern Plains may live hours from the nearest endocrinologist or rheumatologist.

The prescribing workflow typically involves a telehealth visit to review DXA scan results and fracture risk, followed by the prescriber submitting a prior authorization if needed, and then the patient scheduling an in-person injection at a local clinic, infusion center, or primary care office. Some practices in the Denver metro area have adopted a hybrid model where the endocrinologist manages the patient via telehealth while the local primary care office administers the injection and monitors for the 15-minute post-injection observation period.

According to the Bone Health and Osteoporosis Foundation, approximately 10 million Americans have osteoporosis and another 44 million have low bone density, yet treatment rates remain below 25% even among patients who have already sustained a hip fracture [13]. Telehealth access has the potential to close that gap in underserved regions of Colorado.

Comparing Prolia to Alternatives Available in Colorado

For patients facing cost barriers with Prolia, several alternatives are available at significantly lower prices in Colorado. Each carries different efficacy, safety, and convenience tradeoffs.

Oral alendronate (generic Fosamax) costs $10 to $30 per month and is covered by virtually all insurance plans and Colorado Medicaid. The FIT trial (N=6,459) showed alendronate reduced hip fractures by 51% in women with existing vertebral fractures [14]. The primary limitations are gastrointestinal side effects and the requirement to remain upright for 30 minutes after dosing.

Zoledronic acid (generic Reclast), given as a once-yearly IV infusion, runs approximately $300 to $800 per infusion at Colorado infusion centers before insurance. The HORIZON-PFT trial (N=7,765) demonstrated a 70% reduction in vertebral fractures and a 41% reduction in hip fractures over three years [15]. Colorado Medicaid does cover zoledronic acid for osteoporosis, making it the preferred injectable option for Medicaid patients who cannot tolerate oral therapy.

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research & Osteoporosis Center, has stated: "For patients who need an injectable agent and face cost barriers with denosumab, zoledronic acid remains an excellent evidence-based alternative with the added advantage of once-yearly dosing" [16]. This guidance applies directly to Colorado patients navigating Medicaid restrictions on Prolia.

Raloxifene (generic Evista) costs $30 to $60 per month and reduces vertebral fracture risk by 30% to 50%, but it does not reduce hip fracture risk and carries a small increased risk of venous thromboembolism [17].

What Happens if You Stop Prolia

Discontinuing denosumab without transitioning to another antiresorptive carries real clinical risk. Bone density gains reverse rapidly, and rebound vertebral fractures have been documented within 7 to 12 months of the last dose.

A 2017 analysis published in the Journal of Bone and Mineral Research found that patients who discontinued denosumab experienced bone turnover markers that rebounded above baseline levels within 3 to 6 months, with associated rapid bone loss [18]. Multiple vertebral fractures have been reported in patients who stopped denosumab abruptly, including in patients with no prior vertebral fracture history.

The European Calcified Tissue Society issued a position statement recommending that patients who discontinue denosumab should transition to a bisphosphonate (oral or IV) within 6 months of the last Prolia dose to prevent rebound bone loss [19]. This recommendation has direct cost implications for Colorado patients: if a patient starts Prolia but later loses insurance coverage or faces a formulary change, the prescriber must plan for transition therapy rather than simple discontinuation.

Colorado patients on Medicaid who were previously on commercial insurance and receiving Prolia face a particularly difficult situation. The Medicaid formulary does not cover denosumab for osteoporosis, meaning a coverage transition could force an abrupt discontinuation unless the prescriber proactively switches to zoledronic acid or an oral bisphosphonate.

Discount Programs and Patient Assistance in Colorado

Beyond the Amgen savings card, several programs can reduce Prolia costs for Colorado residents. Amgen's Safety Net Foundation provides Prolia at no cost to uninsured or underinsured patients with household income at or below 300% of the federal poverty level ($46,800 for a single individual in 2026). Application requires proof of income and documentation of insurance denial or lack of coverage [5].

NeedyMeds and RxAssist maintain updated databases of patient assistance programs and may list additional state-specific resources. The Colorado Indigent Care Program (CICP), while primarily covering hospital and clinic services, can sometimes support access to specialty medications through participating providers.

Some Colorado health systems, including UCHealth and SCL Health, have financial assistance policies that may cover the administration cost even if the drug cost is handled separately through a manufacturer program. Patients should ask both their prescriber's office and the administering facility about available financial support before assuming full cash-pay pricing.